CoChat

Lactobacillus rhamnosus probiotic prevents airway function deterioration and promotes gut microbiome resilience in a murine asthma model

Open access

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Allergic asthma is a highly prevalent inflammatory disease of the lower airways, clinically characterized by airway hyperreactivity and deterioration of airway function. Immunomodulatory probiotic bacteria are increasingly being explored to prevent asthma development, alone or in combination with other treatments.In this study, wild-type and recombinant probiotic Lactobacillus rhamnosus GR-1 were tested as preventive treatment of experimental allergic asthma in mice. Recombinant L. rhamnosus GR-1 was designed to produce the major birch pollen allergen Bet v 1, to promote allergen-specific immunomodulation. Administration of wild-type and recombinant L. rhamnosus GR-1 prevented the development of airway hyperreactivity. Recombinant L. rhamnosus GR-1 also prevented elevation of airway total cell counts, lymphocyte counts and lung IL-1β levels, while wild-type L. rhamnosus GR-1 inhibited airway eosinophilia. Of note, a shift in gut microbiome composition was observed after asthma development, which correlated with the severity of airway inflammation and airway hyperreactivity. In the groups that received L. rhamnosus GR-1, this asthma-associated shift in gut microbiome composition was not observed, indicating microbiome-modulating effects of this probiotic.These data demonstrate that L. rhamnosus GR-1 can prevent airway function deterioration in allergic asthma. Bet v 1 expression by L. rhamnosus GR-1 further contributed to lower airway inflammation, although not solely through the expected reduction in T helper 2-associated responses, suggesting involvement of additional mechanisms. The beneficial effects of L. rhamnosus GR-1 correlate with increased gut microbiome resilience, which in turn is linked to protection of airway function, and thus further adds support to the existence of a gut-lung axis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/19490976.2020.1766345

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. (ab) Production of Bet v 1 by the L. rhamnosus GR-1-derived strain CMPG11250 using the NICE expression system. (a) Map of the pCMPG11228 plasmid, a pMEC45 derivative carrying the betv1 gene under the control of the lactococcal inducible nisA promoter (PnisA). The lactococcal pSH71 replicon genes repA and repC and the chloramphenicol resistance cassette (CmR) are indicated. (b) Western blot analysis of Bet v 1 production (dotted rectangle) in the whole-cell protein fraction of nisin-induced CMPG11250. Whole cell protein fraction of wild-type L. rhamnosus GR-1 (wt LGR-1) is depicted for comparison. The L lane represents part of the Precision Plus Protein Kaleidoscope 10–250 kDa protein size ladder. Lanes between the L lane and the wt LGR-1 lane have been removed. rBet v 1 represents purified recombinant His-tagged Bet v 1 used as control. (c) Protocol for testing the effects of intragastric pretreatment with wild-type L. rhamnosus GR-1 (wt LGR-1), or recombinant CMPG11250, on allergic asthma. IG: intragastric instillations; IP: intraperitoneal injections; IN: intranasal instillations; Bet v 1-alum: rBet v 1 with aluminum hydroxide; BP: birch pollen; Microbiome sampling: time points of feces collection for microbiome analysis.
Figure 1. (ab) Production of Bet v 1 by the L. rhamnosus GR-1-derived strain CMPG11250 using the NICE expression system. (a) Map of the pCMPG11228 plasmid, a pMEC45 derivative carrying the betv1 gene under the control of the lactococcal inducible nisA promoter (PnisA). The lactococcal pSH71 replicon genes repA and repC and the chloramphenicol resistance cassette (CmR) are indicated. (b) Western blot analysis of Bet v 1 production (dotted rectangle) in the whole-cell protein fraction of nisin-induced CMPG11250. Whole cell protein fraction of wild-type L. rhamnosus GR-1 (wt LGR-1) is depicted for comparison. The L lane represents part of the Precision Plus Protein Kaleidoscope 10–250 kDa protein size ladder. Lanes between the L lane and the wt LGR-1 lane have been removed. rBet v 1 represents purified recombinant His-tagged Bet v 1 used as control. (c) Protocol for testing the effects of intragastric pretreatment with wild-type L. rhamnosus GR-1 (wt LGR-1), or recombinant CMPG11250, on allergic asthma. IG: intragastric instillations; IP: intraperitoneal injections; IN: intranasal instillations; Bet v 1-alum: rBet v 1 with aluminum hydroxide; BP: birch pollen; Microbiome sampling: time points of feces collection for microbiome analysis.CC BY-NC-ND · PubMed Central
Figure 2. Airway function measurements following preventive treatment with wild-type L. rhamnosus GR-1 and CMPG11250, and allergic asthma induction. (a) Airway resistance (Rn) measurements in response to methacholine (0-20 mg/ml) as a reflection of airway hyperreactivity (AHR), and (b) Airway resistance (Rn) area under the curve (AUC) individual values and group means. (c) Forced expiratory volume as a percentage of baseline measurements at 0.2 s (FEV0.2%) in response to methacholine (0-20 mg/ml). (d) The concentration of provocative compound methacholine (PC20) causing a 20% drop in FEV0.2%. Mice are classified as hyperreactive if PC20 is lower than 20 mg/ml. Groups are labeled according to Figure 1c as follows: Saline: no asthma induction, not pretreated; No pretreatment: allergic asthma, not pretreated; wt LGR-1: allergic asthma, pretreated with wild-type L. rhamnosus GR-1; CMPG11250: allergic asthma, pretreated with recombinant L. rhamnosus GR-1 producing Bet v 1 (CMPG11250). Data are depicted as means. ##p < .01 and ####p < .0001 compared to the saline group; *p < .05, **p < .01 and ****p < .0001 compared to the no pretreatment group, n = 5–7 mice per group.
Figure 2. Airway function measurements following preventive treatment with wild-type L. rhamnosus GR-1 and CMPG11250, and allergic asthma induction. (a) Airway resistance (Rn) measurements in response to methacholine (0-20 mg/ml) as a reflection of airway hyperreactivity (AHR), and (b) Airway resistance (Rn) area under the curve (AUC) individual values and group means. (c) Forced expiratory volume as a percentage of baseline measurements at 0.2 s (FEV0.2%) in response to methacholine (0-20 mg/ml). (d) The concentration of provocative compound methacholine (PC20) causing a 20% drop in FEV0.2%. Mice are classified as hyperreactive if PC20 is lower than 20 mg/ml. Groups are labeled according to Figure 1c as follows: Saline: no asthma induction, not pretreated; No pretreatment: allergic asthma, not pretreated; wt LGR-1: allergic asthma, pretreated with wild-type L. rhamnosus GR-1; CMPG11250: allergic asthma, pretreated with recombinant L. rhamnosus GR-1 producing Bet v 1 (CMPG11250). Data are depicted as means. ##p < .01 and ####p < .0001 compared to the saline group; *p < .05, **p < .01 and ****p < .0001 compared to the no pretreatment group, n = 5–7 mice per group.CC BY-NC-ND · PubMed Central
Figure 3. Total and differential cell counts in BALF (ac) and cytokine levels in lung homogenates (dh) following preventive treatment with wild-type L. rhamnosus GR-1 and recombinant CMPG11250 in a mouse model of allergic asthma. Total BALF cell count (a), eosinophil (b), and lymphocyte (c) counts per mL BALF are depicted, as well as levels of IL-1β (d), the Th2-associated cytokines IL-4 (e), IL-5 (f) and IL-13 (g), and the Th1-associated cytokine IFN-γ (h) in lung tissue. Groups are labeled according to Figure 1c as follows: Saline: no asthma induction, not pretreated; No pretreatment: allergic asthma, not pretreated; wt LGR-1: allergic asthma, pretreated with wild-type L. rhamnosus GR-1; CMPG11250: allergic asthma, pretreated with recombinant L. rhamnosus GR-1 producing Bet v 1 (CMPG11250). Data are depicted as median with interquartile range. #p < .05, ##p < .01 and ###p < .001 compared to the saline group; *p < .05 compared to the no pretreatment group; n = 5–7 mice per group.
Figure 3. Total and differential cell counts in BALF (ac) and cytokine levels in lung homogenates (dh) following preventive treatment with wild-type L. rhamnosus GR-1 and recombinant CMPG11250 in a mouse model of allergic asthma. Total BALF cell count (a), eosinophil (b), and lymphocyte (c) counts per mL BALF are depicted, as well as levels of IL-1β (d), the Th2-associated cytokines IL-4 (e), IL-5 (f) and IL-13 (g), and the Th1-associated cytokine IFN-γ (h) in lung tissue. Groups are labeled according to Figure 1c as follows: Saline: no asthma induction, not pretreated; No pretreatment: allergic asthma, not pretreated; wt LGR-1: allergic asthma, pretreated with wild-type L. rhamnosus GR-1; CMPG11250: allergic asthma, pretreated with recombinant L. rhamnosus GR-1 producing Bet v 1 (CMPG11250). Data are depicted as median with interquartile range. #p < .05, ##p < .01 and ###p < .001 compared to the saline group; *p < .05 compared to the no pretreatment group; n = 5–7 mice per group.CC BY-NC-ND · PubMed Central
Figure 4. Serum antibody levels following preventive treatment with wild-type L. rhamnosus GR-1 and recombinant CMPG11250 in a mouse model of allergic asthma. Bet v 1-specific IgG1 (a), Bet v 1-specific IgG2a (b), ratios of Bet v 1-specific IgG1 to IgG2a (c), total IgE (d), and ratios of total IgE to Bet v 1-specific IgG2a (e) after L. rhamnosus preventive treatment and allergic asthma induction. Groups are labeled according to Figure 1c as follows: Saline: no asthma induction, not pretreated; No pretreatment: allergic asthma, not pretreated; wt LGR-1: allergic asthma, pretreated with wild-type L. rhamnosus GR-1; CMPG11250: allergic asthma, pretreated with recombinant L. rhamnosus GR-1 producing Bet v 1 (CMPG11250). Data are expressed as absorbance at 450 nm and depicted as median with interquartile range. ###p < .001 compared to the saline group; *p < .05 compared to the no pretreatment group, n = 5–7 mice per group.
Figure 4. Serum antibody levels following preventive treatment with wild-type L. rhamnosus GR-1 and recombinant CMPG11250 in a mouse model of allergic asthma. Bet v 1-specific IgG1 (a), Bet v 1-specific IgG2a (b), ratios of Bet v 1-specific IgG1 to IgG2a (c), total IgE (d), and ratios of total IgE to Bet v 1-specific IgG2a (e) after L. rhamnosus preventive treatment and allergic asthma induction. Groups are labeled according to Figure 1c as follows: Saline: no asthma induction, not pretreated; No pretreatment: allergic asthma, not pretreated; wt LGR-1: allergic asthma, pretreated with wild-type L. rhamnosus GR-1; CMPG11250: allergic asthma, pretreated with recombinant L. rhamnosus GR-1 producing Bet v 1 (CMPG11250). Data are expressed as absorbance at 450 nm and depicted as median with interquartile range. ###p < .001 compared to the saline group; *p < .05 compared to the no pretreatment group, n = 5–7 mice per group.CC BY-NC-ND · PubMed Central
Figure 5. (a) Change in alpha diversity (Inverse Simpson) and (b) community shift reflected as Beta diversity (Bray-Curtis) between microbiome composition after pretreatment and after allergic asthma induction. The position of dot for each mouse reflects a temporal shift in microbiome composition (e.g. the gradient between 0 and 1 from very similar to very dissimilar in Panel b). Crossbar depicts median per group; *p < .05 compared to the saline group; n = 5–7 mice per group; (c) Correlation between the calculated beta diversity reflecting a shift in microbiome composition before and after allergic asthma induction, and allergic asthma parameters. Beta diversity (Bray-Curtis) values between samples of individual mice collected after pretreatment and after allergic asthma induction are depicted as dots per mouse. Airway resistance: measure of AHR in response to methacholine; FEV0.2: FEV0.2% of baseline; Total cells BALF: lung total cell counts per ml BALF; Lymphocytes BALF: lung lymphocyte counts per ml BALF; Eosinophils BALF: lung eosinophil counts per ml BALF. Groups are labeled according to figure 1c as follows: Saline: no asthma induction, not pretreated; No pretreatment: allergic asthma, not pretreated; wt LGR-1: allergic asthma, pretreated with wild-type L. rhamnosus GR-1; CMPG11250: allergic asthma, pretreated with recombinant L. rhamnosus GR-1 producing Bet v 1 (CMPG11250).
Figure 5. (a) Change in alpha diversity (Inverse Simpson) and (b) community shift reflected as Beta diversity (Bray-Curtis) between microbiome composition after pretreatment and after allergic asthma induction. The position of dot for each mouse reflects a temporal shift in microbiome composition (e.g. the gradient between 0 and 1 from very similar to very dissimilar in Panel b). Crossbar depicts median per group; *p < .05 compared to the saline group; n = 5–7 mice per group; (c) Correlation between the calculated beta diversity reflecting a shift in microbiome composition before and after allergic asthma induction, and allergic asthma parameters. Beta diversity (Bray-Curtis) values between samples of individual mice collected after pretreatment and after allergic asthma induction are depicted as dots per mouse. Airway resistance: measure of AHR in response to methacholine; FEV0.2: FEV0.2% of baseline; Total cells BALF: lung total cell counts per ml BALF; Lymphocytes BALF: lung lymphocyte counts per ml BALF; Eosinophils BALF: lung eosinophil counts per ml BALF. Groups are labeled according to figure 1c as follows: Saline: no asthma induction, not pretreated; No pretreatment: allergic asthma, not pretreated; wt LGR-1: allergic asthma, pretreated with wild-type L. rhamnosus GR-1; CMPG11250: allergic asthma, pretreated with recombinant L. rhamnosus GR-1 producing Bet v 1 (CMPG11250).CC BY-NC-ND · PubMed Central
Figure 6. Proposed mechanisms of probiotic action of wild-type and recombinant L. rhamnosus GR-1 in the mouse model of birch pollen-induced allergic asthma. Beneficial microbes can interact with intestinal epithelial cells (IECs) and dendritic cells (DC) through microbe-associated molecular patterns (MAMPs) recognized by pattern recognition receptors (PRRs).5–7 In the gut, these and other effects mediated by beneficial bacteria translate to immune signals processed in the gut-associated lymphoid tissue (GALT). Immune cells and signals (e.g. modulatory cytokines) and microbial metabolites can circulate through the blood and lymphatic system, resulting in distant beneficial effects in the asthmatic airways. ↑ indicates enhancement while ↓ indicates inhibition by pretreatment with wild-type or recombinant L. rhamnosus GR-1. AECs: airway epithelial cells; TH2: T helper 2 cell; B: B cell; IL-1β: Interleukin 1 beta.
Figure 6. Proposed mechanisms of probiotic action of wild-type and recombinant L. rhamnosus GR-1 in the mouse model of birch pollen-induced allergic asthma. Beneficial microbes can interact with intestinal epithelial cells (IECs) and dendritic cells (DC) through microbe-associated molecular patterns (MAMPs) recognized by pattern recognition receptors (PRRs).5–7 In the gut, these and other effects mediated by beneficial bacteria translate to immune signals processed in the gut-associated lymphoid tissue (GALT). Immune cells and signals (e.g. modulatory cytokines) and microbial metabolites can circulate through the blood and lymphatic system, resulting in distant beneficial effects in the asthmatic airways. ↑ indicates enhancement while ↓ indicates inhibition by pretreatment with wild-type or recombinant L. rhamnosus GR-1. AECs: airway epithelial cells; TH2: T helper 2 cell; B: B cell; IL-1β: Interleukin 1 beta.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 1

  1. Pellaton C, 2012, Int J Inflam, 686739

Cited by

See all 100

Metadata

Authors
Spacova, I., Van Beeck, W., Seys, S., Devos, F., Vanoirbeek, J., Vanderleyden, J., Ceuppens, J., Petrova, M., & Lebeer, S.
Affiliations
  • University of Antwerp (BE)
  • Research Group Environmental Ecology and Applied Microbiology, Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium
  • KU Leuven (BE)
Corresponding author
  • Petrova, Mariya
  • Lebeer, Sarah
Venue
Gut Microbes
Published
2020-06-10
Volume
11
Issue
6
Pages
1729-1744
ISSN
  • 1949-0976 (ISSN-L)
  • 1949-0984
OpenAlex
W3033599528
Cited by
87
References
54
Citations by year
2026: 11 · 2025: 21 · 2024: 19 · 2023: 10 · 2022: 8 · 2021: 18
FWCI
5.84
Type
journal article
Language
en
Open access
Locations
  • Gut Microbes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
KU Leuven BOF (PF/10/018)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
Lactobacillus rhamnosus GR-1, probiotics, allergic asthma, airway hyperresponsiveness, gut-lung axis, Bet v 1, birch pollen allergen, airway eosinophilia, airway inflammation, IL-1β, T helper 2 response, asthma prevention
MeSH terms
Gastrointestinal Microbiome, Animals, Asthma, Disease Models, Animal, Humans, Lung, Male, Mice, Inbred BALB C, Th2 Cells, Probiotics, Mice, Lacticaseibacillus rhamnosus, Interleukin-1beta

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lactobacillus rhamnosus probiotic prevents airway function deterioration and promotes gut microbiome resilience in a murine asthma model. https://app.cochat.ai/papers/10.1080/19490976.2020.1766345
The paper
Spacova, I., Van Beeck, W., Seys, S., Devos, F., Vanoirbeek, J., Vanderleyden, J., Ceuppens, J., Petrova, M., & Lebeer, S. (2020). Lactobacillus rhamnosus probiotic prevents airway function deterioration and promotes gut microbiome resilience in a murine asthma model. Gut Microbes. https://doi.org/10.1080/19490976.2020.1766345

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.